Thus, not only can the drug combination reduce HDAC levels in vitro in the short term (6 h), but the combination can re-program surviving tumor cells in vivo to make less of these HDACs in tumors over a much longer period of time (weeks). This evidence concerns the gene HDAC9 and neoplasm.